Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068133 · ClinicalTrials.gov registry record · Phase 2
Trial of VLTS-589 in Subjects With Intermittent Claudication
A Phase 2 study, sponsored by Valentis.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00068133 is a Phase 2 study that has completed, run by Valentis. The registered enrollment target is 100 participants.
The verdict
NCT00068133, a Phase 2 study, has completed, sponsored by Valentis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 compared with subjects receiving placebo.
Interventions
- GENETIC Plasmid based Gene Transfer product-VLTS-589
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2003-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068133
The ClinicalTrials.gov registry entry for NCT00068133 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valentis, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plasmid based Gene Transfer product-VLTS-589 is the first listed.
NCT00068133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068133 about?
NCT00068133 is a clinical study titled "Trial of VLTS-589 in Subjects With Intermittent Claudication". The purpose of this study is to evaluate the safety and tolerability of VLTS-589 compared with placebo, administered bilaterally to the lower extremities, in subjects with intermittent claudication and to determine the effect of VLTS-589 in peak walking time (PWT) for subjects receiving VLTS-589 com...
What is the current status of trial NCT00068133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2003-06. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00068133?
The interventions under investigation include: Plasmid based Gene Transfer product-VLTS-589 (GENETIC).
Who is sponsoring clinical trial NCT00068133?
This trial is sponsored by Valentis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.